Authorized Generics Noose Tightens With “Best Price” Proposal, FTC Study

The Federal Trade Commission's decision to study the practice of authorized generics could become moot if the marketing of such products by brand companies becomes financially unattractive due to a potential change in Medicaid "best price" reporting requirements